Kuros 9-month Revenue Up 77%; Raises 2025 Sales Guidance

Kuros Biosciences (KURN.SW) reported strong financial results for the first nine months of 2025, with total group revenue increasing 77% year-over-year to $101.1 million, largely driven by a 76% rise in Direct MagnetOs product sales to $99.7 million. The company's EBITDA surged to $7.4 million from $1.6 million in the prior-year period, with adjusted EBITDA reaching $12.2 million. Following this performance, Kuros Biosciences has raised its full-year 2025 sales guidance, now projecting growth of at least 70%.

Analysis

Kuros Biosciences (KURN.SW) delivered exceptionally strong financial results for the first nine months of 2025, reporting a 77% year-over-year increase in total group revenue to $101.1 million. This robust top-line growth was predominantly fueled by Direct MagnetOs product sales, which surged 76% year-on-year to $99.7 million, highlighting significant market traction for their key offering.

The company also demonstrated substantial improvements in profitability, with EBITDA rising to $7.4 million from $1.6 million in the prior-year period. Adjusted EBITDA similarly saw a strong increase, reaching $12.2 million compared to $6.5 million previously, indicating enhanced operational efficiency.

In response to this strong performance, Kuros Biosciences has raised its full-year 2025 sales guidance, now projecting growth of at least 70%. This upward revision signals management's confidence in continued market demand and the company's execution capabilities within the competitive healthcare and biotech sector.

Key Decisions for Investors

• Investors should closely evaluate Kuros Biosciences' sustained revenue growth and improved profitability as indicators of strong underlying business fundamentals and market acceptance of its core products.
• Consider the implications of the raised 2025 sales guidance, as it suggests potential for continued positive earnings surprises and could warrant a re-evaluation of current valuation models.
• Monitor the company's ability to maintain high growth rates for Direct MagnetOs sales and further expand its market share within the specialized medical device segment.